Since cervical cancer can be prevented in adult women with early detection tests, precise and fast diagnosis of any sign of CIN (I to III) or other high-risk dysplasia is significant. If any pre-cancerous or abnormal suspicious cells are not detected in the conventional detection process (pathology), they could not be treated before the lesion develops into cervical cancer, consequently reducing the patients' survival rate. We developed a system named hypoxia electrochemical assay (HEA), which is based on live detecting the hypoxia glycolytic functions of high risk / premalignant cells based on the H2O2 released from cancer or atypical cells, through reverse Warburg effect and hypoxia assisted glycolysis pathways to distinct the suspicious cone biopsied specimens immediately after removing from the patient. It is well known that many hypoxia glycolysis-associated markers such as HIF1 alpha and CAlX1 are overexpressed during the transition of healthy cervical cells to CIN. This system was tested on in-vitro human fresh cervical samples prepared from 40 patients' candidates for conization through a history of abnormal cells present in their pap smear results. Patients provided consent according to an ethically approved protocol. By considering the pathology reports of HEA-tested regions, a CIN-based scoring of HEA responses was proposed. It showed the accuracy and sensitivity of 95% and 100%, respectively. Also, results show important consistency between CIN-based pathological diagnosis and HEA scoring (p-value<0.0001). A matched clinical diagnostic categorization between the pathological results of tested tissues and electrochemical response of released H2O2 was proposed based on CIN categorization. Further pathological evaluation of the tested samples showed that this approach covered about 10% of CIN lesions missed by conventional pathology of assayed patients.